No products in the cart.
#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer
Click to read the study in JAMA Oncology.
Tag: trastuzumab
#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer
Click to read the study in The Lancet Oncology.
#VisualAbstract: Margetuximab improves progression-free survival in patients with ERBB2⁺ advanced breast cancer compared to trastuzumab
Click to read the study in JAMA Oncology.
#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer
Click to read the study in JAMA Network Open
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
1. In this randomized, placebo controlled study of HER2-positive breast cancer patients receiving trastuzumab, use of preventative lisinopril or carvedilol ...
The KATHERINE trial: trastuzumab emtansine more effective than trastuzumab alone for treating residual HER2-positive breast cancer
1. Patients with residual human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy and HER2 targeted therapy had ...
Trastuzumab associated with increased reversible cardiac changes
Image: PD 1. At 8 years median follow-up, trastuzumab treatment for HER2-positive breast cancer is associated with slightly increased rates ...
One-year of Herceptin preferable to two-year regimen
Image: PD 1. One year of adjuvant Herceptin (trastuzumab) has similar efficacy as a two-year regimen. 2. One-year regimen was ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.